Medpace Holdings, Inc.

NasdaqGS:MEDP

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

Location

United States

Market Cap

USD 8.89 B

Share Price

USD 309.36

Avg Daily Volume

494,823

Change (1 day)

2.20%

Change (1 year)

-22.78%

Change (YTD)

-6.88%

Medpace Holdings, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2025: 22.51%

Medpace Holdings, Inc. EBITDA Margin is 22.51% for the Trailing 12 Months (TTM) ending March 31, 2025, a 15.00% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Medpace Holdings, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2024 was 19.58%, a -5.21% change year over year.
Medpace Holdings, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2023 was 20.65%, a 5.43% change year over year.
Medpace Holdings, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2022 was 19.59%, a -6.14% change year over year.
Medpace Holdings, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2021 was 20.87%, a 18.92% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	EBITDA Margin	Net Income Margin	EBT Margin	Operating Income Margin

NasdaqGS: MEDP

Medpace Holdings, Inc.

CEO	Dr. August James Troendle M.D.
IPO Date	Aug. 11, 2016
Location	United States
Headquarters	5375 Medpace Way
Employees	5,900
Sector	🏥 Health Care
Industries Clinical Trials

Description

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.